iBio Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-04-01
- Employees
- 23
- Market Cap
- $16.5M
- Website
- http://www.ibioinc.com
- Introduction
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timeli...
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
iBio, Inc. reports FY2024 financial results, highlighting significant progress in AI-driven antibody immunotherapies, including collaborations, technology advancements, and financial improvements. Key developments include the launch of ShieldTx™, sale of PD-1 asset to Otsuka, and collaboration with AstralBio. The company strengthened its financial position through debt elimination, capital raises, and strategic transactions, reducing net loss to $24.9 million from $65 million in FY2023. iBio holds $14.4 million in cash and equivalents as of June 30, 2024.
© Copyright 2024. All Rights Reserved by MedPath